You are now leaving the Kedrion website. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES

HIGHLIGHTS

CORPORATE

Kedrion stronger in North America and further committed to rare diseases

Agreement with Canadian-based Liminal BioSciences signed on June 22nd

read more 

CORPORATE

Kedrion announces the appointment of a new CEO

Val Romberg from the USA, one of the most esteemed managers in the industry

read more 

CORPORATE

COVID-19. Kedrion partners with Columbia University Irving MC

Kedrion and Columbia University release video statements

read more 
  1. CORPORATE - 30-06-2021

    Kedrion stronger in North America and further committed to rare diseases

    Agreement with Canadian-based Liminal BioSciences signed on June 22nd

    read more 
  2. CORPORATE - 07-10-2020

    Kedrion announces the appointment of a new CEO

    Val Romberg from the USA, one of the most esteemed managers in the industry

    read more 
  3. CORPORATE - 01-09-2020

    KEDPLASMA GmbH changes its name to Kedrion Biopharma GmbH

    Further step towards an even stronger focus on patients in Europe

    read more 
  4. CORPORATE - 23-07-2020

    COVID-19. Kedrion partners with Columbia University Irving MC

    Kedrion and Columbia University release video statements

    read more 

Pages

For more information please contact: [email protected]